Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central

Background: Precocious puberty may reduce final adult height, and affected children may suffer social and emotional problems. The efficacy of treatment with a long acting agonist analogue of the gonadotropin releasing hormone (aLHRH) has been well demonstrated. Aim: To evaluated the efficacy of a ne...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mericq G,M Verónica, Youlton R,Ronald, Willshaw Z,M Eugenia
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2006
Materias:	Gonadotropins Leuprolide Puberty, precocious
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872006000700003
record_format	dspace
spelling	oai:scielo:S0034-988720060007000032006-08-29Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz centralMericq G,M VerónicaYoulton R,RonaldWillshaw Z,M Eugenia Gonadotropins Leuprolide Puberty, precocious Background: Precocious puberty may reduce final adult height, and affected children may suffer social and emotional problems. The efficacy of treatment with a long acting agonist analogue of the gonadotropin releasing hormone (aLHRH) has been well demonstrated. Aim: To evaluated the efficacy of a new formulation of aLHRH (leuprolide, Lupron®) for the suppression of gonadotropin activation and clinical signs of puberty. Material and methods: Eleven children (ten females) with idiopathic central precocious puberty, with a mean chronological age of 7.5±1.8 years and a bone age of 9.7±1.8 years were recruited. Testicular volume in the male was 15 ml. In females, Tanner stage for breast development was between 2-4 and mean ovarian volume was 2.3±0.8 ml. They were treated during 18 months with aLHRH, 11.25 mg administered intramuscularly every three months. Results: Clinical, hormonal and ultrasonographic signs of puberty regressed in all patients. The degree of suppression of LH was 87.7±5.1% at the end of the 18 months. No significant changes in bone mineral content were observed during the treatment period. Conclusions: Leuprolide (aLHRH) 11.25 mg, injected every three months, is effective for the control of central precocious puberty and allows to reduce the number of yearly injections from 12 to 4info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.7 20062006-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700003es10.4067/S0034-98872006000700003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Gonadotropins Leuprolide Puberty, precocious
spellingShingle	Gonadotropins Leuprolide Puberty, precocious Mericq G,M Verónica Youlton R,Ronald Willshaw Z,M Eugenia Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
description	Background: Precocious puberty may reduce final adult height, and affected children may suffer social and emotional problems. The efficacy of treatment with a long acting agonist analogue of the gonadotropin releasing hormone (aLHRH) has been well demonstrated. Aim: To evaluated the efficacy of a new formulation of aLHRH (leuprolide, Lupron®) for the suppression of gonadotropin activation and clinical signs of puberty. Material and methods: Eleven children (ten females) with idiopathic central precocious puberty, with a mean chronological age of 7.5±1.8 years and a bone age of 9.7±1.8 years were recruited. Testicular volume in the male was 15 ml. In females, Tanner stage for breast development was between 2-4 and mean ovarian volume was 2.3±0.8 ml. They were treated during 18 months with aLHRH, 11.25 mg administered intramuscularly every three months. Results: Clinical, hormonal and ultrasonographic signs of puberty regressed in all patients. The degree of suppression of LH was 87.7±5.1% at the end of the 18 months. No significant changes in bone mineral content were observed during the treatment period. Conclusions: Leuprolide (aLHRH) 11.25 mg, injected every three months, is effective for the control of central precocious puberty and allows to reduce the number of yearly injections from 12 to 4
author	Mericq G,M Verónica Youlton R,Ronald Willshaw Z,M Eugenia
author_facet	Mericq G,M Verónica Youlton R,Ronald Willshaw Z,M Eugenia
author_sort	Mericq G,M Verónica
title	Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
title_short	Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
title_full	Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
title_fullStr	Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
title_full_unstemmed	Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
title_sort	efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central
publisher	Sociedad Médica de Santiago
publishDate	2006
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700003
work_keys_str_mv	AT mericqgmveronica efectividaddelaterapiaconleuprolideacetatodedepositocadatresmesesenpubertadprecozcentral AT youltonrronald efectividaddelaterapiaconleuprolideacetatodedepositocadatresmesesenpubertadprecozcentral AT willshawzmeugenia efectividaddelaterapiaconleuprolideacetatodedepositocadatresmesesenpubertadprecozcentral
_version_	1718436269339443200

Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central

Ejemplares similares